-
Beyond the Growth Chart: New Long-Term Data on VOXZOGO® for Achondroplasia
NASDAQ: $BMRN The landscape of pediatric endocrinology is shifting. At the Pediatric Endocrine Society’s (PES) 2026 Annual Meeting in San Francisco, new data presented by BioMarin Pharmaceutical Inc. has provided a clearer picture of how long-term treatment with VOXZOGO® (vosoritide) impacts children with achondroplasia. While height is often the most visible metric in skeletal dysplasias,…
-
New Two-Year Data on CRENESSITY® (crinecerfont) Shows Lasting Health Benefits for Children with Classic Congenital Adrenal Hyperplasia
NASDAQ: $NBIX Recent findings presented at the Pediatric Endocrine Society 2026 Annual Meeting offer a promising outlook for the pediatric community living with classic congenital adrenal hyperplasia (CAH). Neurocrine Biosciences has released new two-year data from the Phase 3 CAHtalyst® Pediatric study, revealing that long-term treatment with CRENESSITY® (crinecerfont) provides durable hormone control and allows…
-
Viatris Advances Contraceptive Care: New Data on Weekly Low-Dose Patch to be Presented at ACOG 2026
NASDAQ: $VTRS As we approach the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting in Washington, D.C., the medical community is turning its attention toward significant advancements in reproductive health. Viatris Inc. recently announced it will present six new abstracts regarding its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly…
-
Kodiak Sciences Advances Pipeline and Unveils New Clinical Data for KSI-101 in Uveitis Treatment
NASDAQ: $KOD Kodiak Sciences Inc. has announced significant progress in its clinical and scientific programs, with plans to present new data at the 2026 American Uveitis Society (AUS) Meeting and the Association for Research in Vision and Ophthalmology (ARVO) Meeting. These updates center on the clinical performance of KSI-101 in treating macular edema secondary to…
-
Expanding Global Protection: Genprex Secures Key Patent for Reqorsa® Gene Therapy in Israel
NASDAQ: $GNPX In a significant move to strengthen its international intellectual property portfolio, clinical-stage gene therapy company Genprex, Inc. (NASDAQ: GNPX) recently announced that the Israel Patent Office (ILPO) has officially granted a patent covering the use of its proprietary Reqorsa® gene therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for cancer treatment. Strategic Intellectual…
-
Advancing Crohn’s Disease Treatment: The Potential of RedHill’s RHB-204
NASDAQ: $RDHL The landscape of Crohn’s disease (CD) treatment may be on the cusp of a significant shift. RedHill Biopharma Ltd. recently announced promising in vitro testing results for RHB-204, a next-generation oral formulation that represents a targeted therapeutic approach to the condition. By focusing on Mycobacterium avium subspecies paratuberculosis (MAP), RedHill is pursuing a strategy…
-
Advancing Large-Bore Venous Access: New Study Validates VASCADE MVP® XL Performance
NYSE: $HAE In the rapidly evolving field of cardiac electrophysiology, the precision of venous access closure is as critical as the primary procedure itself. Haemonetics Corporation recently announced compelling new clinical evidence regarding its VASCADE MVP® XL venous vascular closure system, marking a significant milestone for procedural safety and efficiency in large-bore venous access. The…
-
New Two-Year Data Supports Long-Term Management of Classic Congenital Adrenal Hyperplasia with CRENESSITY®
NASDAQ: $NBIX For individuals living with classic congenital adrenal hyperplasia (CAH), the standard of care has long presented a difficult dilemma. While patients require glucocorticoids (GCs) to survive, the historical reliance on supraphysiologic doses—doses higher than what the body naturally produces—has carried a heavy burden of long-term health risks, including metabolic complications, bone density loss,…
-
Advancing Oncology: Mount Sinai Health System Partners with SOPHiA GENETICS to Elevate Precision Cancer Care
NASDAQ: $SOPH In a significant move for the future of precision medicine, the Mount Sinai Health System has announced a strategic collaboration with SOPHiA GENETICS. This partnership marks a new chapter for one of the nation’s most prestigious academic health systems, as it integrates the AI-powered SOPHiA DDM™ Platform to refine its genomic testing capabilities…
-
NeuroSense’s PrimeC Shows Remarkable 65% Reduction in ALS Mortality Risk and Over 14-Month Survival Extension
NASDAQ: $NRSN NeuroSense Therapeutics Ltd., a biotechnology company concentrating on developing treatments for neurodegenerative conditions, has recently released compelling long-term survival data from its completed PARADIGM Phase 2b clinical trial assessing PrimeC for amyotrophic lateral sclerosis (ALS). This extended analysis confirms a clinically significant and statistically robust improvement in overall survival for patients treated with…
-
SOPHiA GENETICS Expands U.S. Footprint with Agreements with Two Major Integrated Health Systems
NASDAQ: $SOPH SOPHiA GENETICS, a recognized leader in AI-driven precision medicine, has significantly augmented its presence in the United States through agreements with two substantial, integrated healthcare systems. This expansion marks a pivotal moment in bringing advanced genomic analysis to a wider patient population across key regions. These two newly integrated institutions represent some of…
-
Viking Therapeutics Announces Q4 and Full-Year 2025 Financial Results Date
NASDAQ: $VKTX Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and endocrine diseases, has officially announced the date for its upcoming financial report. Investors and interested parties can anticipate the company’s financial results for the fourth quarter and the full year ended December 31, 2025, which will be released…
-
Rigel Strengthens Leadership with Appointment of Michael P. Miller to Board of Directors
NASDAQ: $RIGL Rigel Pharmaceuticals, Inc. recently announced a significant addition to its leadership structure with the appointment of Michael P. Miller to its Board of Directors, effective immediately. Mr. Miller brings a wealth of experience in the biotechnology and pharmaceutical sectors, promising to contribute valuable strategic insights as Rigel continues to advance its pipeline and…
-
Avidity Biosciences Sets Record Date for Potential Spin-Off of RNA Therapeutics Business
NASDAQ: $RNA Avidity Biosciences, Inc. has recently announced a significant corporate development concerning its RNA therapeutics business. The company has established an expected record date for the potential separation of its RNA therapeutics business into an independent, publicly traded entity. The Potential Spin-Off Explained In a move designed to potentially maximize shareholder value and allow…
-
ADC Therapeutics Strengthens Team with New Employee Inducement Grants
NYSE: $ADCT ADC Therapeutics SA, a commercial-stage, late-stage biotechnology company focused on the development and commercialization of antibody drug conjugates (ADCs) for patients suffering from cancer, recently announced a significant commitment to its growing workforce. In a filing dated December 17, 2024, the company disclosed the granting of equity awards to newly hired employees under…
-
Anixa Biosciences Advances CAR-T Therapy with U.S. Adopted Name Approval
NASDAQ: $ANIX Anixa Biosciences, Inc., a biotechnology company focused on the development of innovative cancer therapies, has reached a significant milestone in the progression of its CAR-T cell therapy candidate. The company announced that the United States Adopted Names (USAN) Council has approved the non-proprietary name for its novel CAR-T therapy. This approval of a…
-
Edgewise Therapeutics Announces Inducement Grants Under Nasdaq Rules
NASDAQ: $EWTX Edgewise Therapeutics Reports Inducement Grants as Permitted by Nasdaq Listing Rules Edgewise Therapeutics, Inc., a company focused on developing transformative therapies for muscular dystrophies, has recently announced the issuance of new equity awards. These grants were made as inducement awards to newly hired non-executive employees, a practice fully compliant with the Nasdaq Stock…